Articles tagged with: Stem Cell Transplant
The 48th annual meeting of the American Society of Clinical Oncology (ASCO) will take place Friday, June 1, through Tuesday, June 5, in Chicago.
More than 25,000 clinical specialists from all over the world are expected to attend the five-day meeting to discuss the current research in cancer treatment and care. The theme for this year’s meeting is “Collaborating to Conquer Cancer.”
The meeting will include many presentations and seminars focused specifically on multiple myeloma. The ASCO website currently lists nearly 50 myeloma-based presentations (included under “lymphoma and plasma cell …
When my stem cells were harvested and put in the deep freeze in June 2010, my hematologist said the timing for the transplant was not yet critical. As long as my blood counts remained reasonably level, and as long I could tolerate the side effects of Revlimid (lenalidomide) and dexamethasone (Decadron), he felt I could postpone the procedure.
A few weeks after the stem cell harvest, I retired from my job because of dexamethasone-related side effects (see my related Beacon column). I also believed the stem cell …
The results of an Italian Phase 3 study show that consolidation therapy with a combination of Velcade, thalidomide, and dexamethasone is more effective in newly diagnosed multiple myeloma patients than treatment with thalidomide and dexamethasone alone.
Specifically, the three-drug regimen led to higher rates of complete responses, as well as longer progression-free survival, compared to the two-drug regimen.
“Analyses performed in our study demonstrate that VTD [Velcade-thalidomide-dexamethasone] consolidation therapy significantly contributed to improved clinical outcomes,” said lead study investigator Dr. Michele Cavo from the Seragnoli Institute of Hematology in Bologna, …
A recent study suggests that Mozobil helps multiple myeloma patients with prior exposure to Revlimid collect enough stem cells for transplantation.
The study investigators conclude that stem cell mobilization with the aid of a growth factor plus Mozobil (plerixafor) is an effective upfront approach for multiple myeloma patients who plan to undergo a transplant, regardless of previous Revlimid (lenalidomide) exposure.
“With growth factor and preemptive Mozobil, virtually all patients with multiple myeloma can have successful stem cell collection,” said Dr. Luciano Jose Costa of the Medical University of South …
The results of a recent Phase 1/2 study suggest that a combination of Velcade and melphalan followed by two back-to-back stem cell transplants is active and well-tolerated in multiple myeloma patients who failed to respond to their initial therapy or who have plasma cell leukemia, a highly aggressive form of myeloma.
Although the response and survival rates for this regimen did not improve upon those for previously tested regimens, the study authors contend that further studies of this novel Velcade-melphalan combination should be conducted to better understand the synergistic properties …